Scientists set out to connect the dots on long COV
Post# of 148185
(Total Views: 465)
Posted On: 04/29/2021 12:05:33 PM
Scientists set out to connect the dots on long COVID
Interesting article just published in Nature Methods about long Covid. I suspect many are underestimating the potential market for LL with Long Haulers. Here are some excerpts and link:
https://www.nature.com/articles/s41592-021-01145-z
_______________________________________________________
Too many have died from COVID-19, but fortunately many have recovered, most without the need for hospitalization. Yet many recoverees are plagued by often life-derailing symptoms such as breathing problems, deep fatigue, joint pain, ‘brain fog’ and heart palpitations. Long COVID will affect, and already is affecting, millions of people and needs to be taken seriously, says Adrian Hayday, an immunologist at the Francis Crick Institute. Data are still emerging, says Karolinska Institute researcher Petter Brodin, but to a first approximation it appears that 70–80% of people experiencing severe acute reactions to COVID-19 are men, whereas women comprise 70–80% of those suffering from long COVID. The average age of long-haul patients is 40, says neuroimmunologist Avi Nath, who is intramural clinical director of the National Institute for Neurological Disorders and Stroke (NINDS) at the US National Institutes of Health (NIH). “They are in the most productive phases of their lives.”
Deep sleuthing is getting underway to explore scientists’ hunches on the underpinnings of long-haul COVID. Resources are being set up to explore how to alleviate symptoms. The UK National Health Service, for example, has set up a network of long-COVID specialist clinics, as have academic medical centers in the US and elsewhere.
The NIH has launched a research initiative focusing on the Post-Acute Sequelae of SARS-CoV-2 Infection (PASC), which currently has $1.15 billion in funding. A cohort of patients will be recruited and followed, and their bodies and biopsies will be scrutinized using a broad assortment of technologies. The NIH PASC Initiative will assess, among other aspects, how many people develop such symptoms after SARS-CoV-2 infection and will explore their underlying causes.
Interesting article just published in Nature Methods about long Covid. I suspect many are underestimating the potential market for LL with Long Haulers. Here are some excerpts and link:
https://www.nature.com/articles/s41592-021-01145-z
_______________________________________________________
Too many have died from COVID-19, but fortunately many have recovered, most without the need for hospitalization. Yet many recoverees are plagued by often life-derailing symptoms such as breathing problems, deep fatigue, joint pain, ‘brain fog’ and heart palpitations. Long COVID will affect, and already is affecting, millions of people and needs to be taken seriously, says Adrian Hayday, an immunologist at the Francis Crick Institute. Data are still emerging, says Karolinska Institute researcher Petter Brodin, but to a first approximation it appears that 70–80% of people experiencing severe acute reactions to COVID-19 are men, whereas women comprise 70–80% of those suffering from long COVID. The average age of long-haul patients is 40, says neuroimmunologist Avi Nath, who is intramural clinical director of the National Institute for Neurological Disorders and Stroke (NINDS) at the US National Institutes of Health (NIH). “They are in the most productive phases of their lives.”
Deep sleuthing is getting underway to explore scientists’ hunches on the underpinnings of long-haul COVID. Resources are being set up to explore how to alleviate symptoms. The UK National Health Service, for example, has set up a network of long-COVID specialist clinics, as have academic medical centers in the US and elsewhere.
The NIH has launched a research initiative focusing on the Post-Acute Sequelae of SARS-CoV-2 Infection (PASC), which currently has $1.15 billion in funding. A cohort of patients will be recruited and followed, and their bodies and biopsies will be scrutinized using a broad assortment of technologies. The NIH PASC Initiative will assess, among other aspects, how many people develop such symptoms after SARS-CoV-2 infection and will explore their underlying causes.
(5)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼